A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model....

The rollout of vaccines is on in an attempt to achieve population immunity against the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)....

The effect of different neutralizing antibodies, both vaccine-elicited and from convalescent sera, suggests new variants are emerging that can evade the human immune response. The severe acute respiratory...

Evolutionary ecology theory offers avenues to anticipate the future behavior of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. The repeated emergence of more infectious and...

The coronavirus disease 2019 (COVID-19) pandemic continues to ravage worldwide, infecting over 118.15 million people. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection...

New York has the first case of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526, picked up by genomic surveillance research from Columbia University. The findings...

Prior to the emergence of new mutants of the coronavirus, such as the British variant B.1.1.7, the SARS-CoV-2 variant named D614G had already mutated from the original SARS-CoV-2 pathogen that triggered...

The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines...

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus...